The tissue samples are being gathered as part of a PET-PSMA trial in which patients with oliogemastatic disease are being managed with extirpative surgery. A total of 6 samples have been gathered to date and 3 samples have been successfully grown in on Collagen type 1 coated plates using novel media. PSA ELISA test and RT-qPCR technology (PSA, AR, FKBP5 and TMPRSS) was used to validate the cells cultures were of prostate cancer origin.
Dr. Joshi presents a single patient example to show the potential implications for this technology. The patient was a 67 year old male who developed biochemical recurrence following radical prostatectomy with a PSA 1.5 ng/dl. The patient underwent a PSMA-PET CT scan which showed a PET avid node in the right hemi-pelvis with no additional sites of disease. The patent underwent lymphadenectomy and the PET-avid node sent for tissue culture. The tumor was able to be successfully cultured at a minimum of 2 weeks. Following validation studies with PSA ELISA and RT-qPCR, drug screening test were performed. Drug screen revealed a marked response to Docetaxel, Cabazitaxel and minimal effect with anti-androgen therapy (Enzalutamide and Bicalutamide). Whole exome and RNA sequencing analysis is underway to validate the results from the drug screen.
In conclusion, prostate cancer cell lines can be successfully cultured in vitro using organoid technology. The ability to successfully grow prostate cancer cell in vitro allows for sequencing analysis and drug screening for each specific patient allowing for tailored treatment regimens with the hope they improved oncological outcomes and decrease toxicity profiles.
Presented By: Andre Joshi, MBBS
Written By: Andres F. Correa, Fox Chase Cancer Center, Philadelphia, PA
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA